awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38550459-23D9A8AE-81DD-4719-82FC-A588CBFD1D0F
Q38550459-23D9A8AE-81DD-4719-82FC-A588CBFD1D0F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38550459-23D9A8AE-81DD-4719-82FC-A588CBFD1D0F
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.
P2860
Q38550459-23D9A8AE-81DD-4719-82FC-A588CBFD1D0F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38550459-23D9A8AE-81DD-4719-82FC-A588CBFD1D0F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
322ab9d82bcb68582a7bfacfa1238668b22b667c
P2860
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.